Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMs), Biosimilars, Generics & Vaccines

  • ID: 2887502
  • Report
  • Region: India
  • 183 Pages
  • Kelly Scientific Publications
1 of 5

FEATURED COMPANIES

  • Aurobindo Pharma
  • Cipla
  • Dr Reddy’s Laboratories
  • Mankind Pharma
  • Piramal Group
  • Reliance Life Sciences
  • MORE
PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 333 tables & figures. The Indian pharmaceutical market (IPM) is presented as follows:

- By Company (e.g., CIPLA, SUN PHARMA, RANBAXY, PIRAMAL, ZYDUS CADILA, MANKIND, LUPIN)
- By Segment (FORMULATIONs, APIs, BIOSIMILARs, CRAMS, GENERICS, VACCINES)
- By Therapeutic Area (e.g., Cardiovascular, Diabetes, Cancer, Respiratory)
- By Disease Category (Acute, Chronic)

A wealth of financial information is provided including:

- Up-to-date company financials, sales & revenue figures
- India GDP, economic growth, export (bulk drug, formulations) figures
- Indian health expenditure as a function of GDP
- Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
- Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)

SWOT, Economic and Business Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the IPM
- Top five fastest growing Indian pharma market segments
- Top five emerging opportunities within the IPM
- Top pharmaceutical companies within the IPM by market share and revenue
- Multinational penetration into the Indian Pharma Market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top Indian pharmacos
- Economic indicators, trade policy, merchandise and commercial trade statistics
- Gross Domestic Product of India, historic and projection analysis
- Indian economic outlook in comparison to advanced economies

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

- An in-depth understanding of the Indian biopharmaceutical market and it’s environment
- Current market facts, figures and product lines of key players in the industry
- An insight into how generic therapeutics will propagate the Indian biopharmaceutical market
- Knowledge of how the Indian biopharma market will integrate into the global healthcare market
- Information on key government policies
- Strategies on how to adapt and restructure current business models to this industry
- Clients may also use referenced tables, figures and data for their own reports and presentations

This report will tell you if the companies mentioned are:

- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aurobindo Pharma
  • Cipla
  • Dr Reddy’s Laboratories
  • Mankind Pharma
  • Piramal Group
  • Reliance Life Sciences
  • MORE
1.0 Summary

1.1 Objectives of Report

1.2 Scope of Study

1.3 Data Sources and Methodology

1.4 Key Findings and Observations

1.5 Executive Summary

2.0 Epidemiology and Disease Overview

2.1 Cardiovascular Disease

2.2 Infectious Disease

2.3 Respiratory Infections

2.4 Tuberculosis

2.5 HIV

2.6 Hepatitis

2.7 Typhoid Fever

2.8 Dengue Fever

2.9 Diabetes

2.10 Cancer

2.11 Chronic Respiratory Disease- Asthma and COPD

3.0 Twelfth Five Year Plan – A Boost for Scientific Research and Development

4.0 Economic and Business Environment

4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics

4.2 Gross Domestic Product of India, Historic and Projection Analysis

4.3 Global and India Economic Outlook 2010-2013

4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe)

5.0 Indian Pharmaceutical Industry

5.1 Overview

5.2 Evolution of Indian Pharmaceutical Industry

5.3 Pharmaceutical Export Market

5.4 Formulations Market

5.5 Active Pharmaceutical Ingredient Market

5.6 Biosimilar Market

5.7 Contract Research and Manufacturing Service (CRAMS)

5.8 Indian Pharmaceutical Industry Market

5.9 Evaluation of Market Share by Therapeutic Area

5.10 Indian Biotechnology Industry

5.11 Generic Drug Market

5.12 Vaccine Industry in India

5.13 Key Players

5.14 R&D Spending on the Increase

5.15 Important Market Trends Within the Indian Pharmaceutical Industry

6.0 Indian Pharmaceutical Company Profiles and Financial Data

6.1 Aurobindo Pharma

6.2 Bharat Serums and Vaccines Ltd

6.3 Biocon Biopharmaceuticals

6.4 Cipla

6.5 Divis Laboratories

6.6 Dr Reddy’s Laboratories

6.7 Lupin

6.8 Mankind Pharma

6.9 Panacea Biotech

6.10 Piramal Group

6.11 Ranbaxy Laboratories

6.12 Reliance Life Sciences

6.13 Serum Institute of India

6.14 Sun Pharmaceuticals

6.15 Zydus Cadila

7.0 SWOT Analysis of Indian Pharmaceutical Market

7.1 Growth Factors

7.2 Strengths of Indian Pharmaceutical Industry

7.3 Main Weaknesses

7.4 Significant Opportunities within the Indian Pharmaceutical Industry

7.5 Threats and Considerations

8.0 Company Directory and Key People

8.1 Aurobindo Pharma

8.2 Bharat Serums and Vaccines Ltd

8.3 Biocon Biopharmaceuticals

8.4 Cipla

8.5 Divis laboratories

8.6 Dr Reddy’s Laboratories

8.7 Lupin

8.8 Panacea Biotech

8.9 Reliance Life Sciences

9.0 Appendix

9.1 Comprehensive List of Pharmaceutical Company’s in India

List of Exhibits
Exhibit 2.1: Key Statistics: India

Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011

Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030

Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India

Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030

Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World

Exhibit 2.7: Cardiovascular Mortality by Indian State

Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India

Exhibit 2.9: Distribution of Cause of Death in Children under Five, India

Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia

Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children

Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present

Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates

Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases

Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-infection

Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011

Exhibit 2.17: Countries That Have Notified of at Least One XDR-TB Case

Exhibit 2.18: TB Vaccine Development Pipeline 2012

Exhibit 2.19: HIV Prevalence in India 2004-2009

Exhibit 2.20: Routes of HIV Transmission in India

Exhibit 2.21: Global Hepatitis E Virus Endemicity

Exhibit 2.22: Prevalence of Diabetes by Indian Region

Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes

Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes

Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female

Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men

Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India – Women

Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes

Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes

Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer’s in India

Exhibit 2.30: Mortality Rate (per 100,000) Attributable to Chronic Obstructive Pulmonary Disease Globally
Exhibit 3.1: India’s Twelve Year Plan – Key Points in Relation to Science Research and Development

Exhibit 3.2: Budget for Specific Scientific Departments under India’s Twelfth Five Year Plan

Exhibit 4.1: World Trade Organisation Basic Indicators on India

Exhibit 4.2: World Trade Organisation Trade Policy of India

Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India

Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India

Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India

Exhibit 4.6: India GDP Figures 2011-2018

Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010

Exhibit 4.8: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013

Exhibit 4.9: Global, Emerging Market & Developing Countries & India Economic Growth Change 2010-2013

Exhibit 4.10: Global, Emerging Market, Developing Countries & Russia Economic Growth Change 2010-2013

Exhibit 4.11: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013

Exhibit 4.12: Global, Emerging Market & Developing Countries & Brazil Economic Growth Change 2010-2013

Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013

Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017

Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013

Exhibit 4.16: France, Germany and Italy Gross Domestic Product per capita Forecast 2010-2017

Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013

Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013

Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017

Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry

Exhibit 5.2: Evolution Timeline of The Indian Pharmaceutical Industry

Exhibit 5.3: Indian Pharmaceutical Industry IPM and Exports 2003-2015

Exhibit 5.4: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015

Exhibit 5.5: Top 50 Exporting Pharmaceutical Companies in India

Exhibit 5.6: Indian Pharmaceutical Industry Formulation Exports 2003-2015

Exhibit 5.7: Indian Pharmaceutical Industry Domestic Formulations 2003-2015

Exhibit 5.8: Geographic Distribution of India’s Active Pharmaceutical Ingredient Exports, 2012

Exhibit 5.9: Current Trends of the Global Biosimilar Market

Exhibit 5.10: Main Therapeutic Areas of the Future Biosimilar Market

Exhibit 5.11: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry

Exhibit 5.12: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry

Exhibit 5.13: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015

Exhibit 5.14: Drivers and Resistors of the Indian CRAMS/CMO Industry

Exhibit 5.15: Advantages of Contract Research Organizations in India

Exhibit 5.16: Challenges of Contract Research Organizations in India

Exhibit 5.17: Areas of Growth and Potential for Indian Contract Research Organisation’s

Exhibit 5.18: Indian Pharmaceutical Market Revenue 2005-2020

Exhibit 5.19: Generic Drug, Over the Counter and Patened Drug Sub-Market Revenue Share

Exhibit 5.20: India’s Pharmaceutical Market Share by Value in the Asia-Pacific Region

Exhibit 5.21: Leading Players of the Indian Pharmaceutical Market

Exhibit 5.22: Top 20 Biotechnology Companies in India by Revenue FY2013

Exhibit 5.23: India - Significant Economic Indicators

Exhibit 5.24: Positive Factors Influencing the Indian Pharmaceutical Market

Exhibit 5.25: Quantitative Market Share of Acute and Chronic Therapy in India

Exhibit 5.26: Multinational Company Penetration into Indian Pharmaceutical Market

Exhibit 5.27: Key Factors Influencing Leading Player Position in India Pharma Market

Exhibit 5.28: Partnerships Between International Pharmaco’s and Domestic API Partners

Exhibit 5.29: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013-Table Format

Exhibit 5.30: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013- Pie Chart Format

Exhibit 5.31: Indian Pharmaceutical Market Share (%) by Therapeutic Area

Exhibit 5.32: Top Five Fastest Growing Indian Pharma Market Segments

Exhibit 5.33: Top Biotechnology Companies by Revenue FY2013 (Barchart)

Exhibit 5.34: Top 20 Biotechnology Companies in India by Revenue FY2013 Table

Exhibit 5.35: Top Five Emerging Opportunities within the Indian Pharmaceutical Market

Exhibit 5.36: Top Five Indian Vaccine Manufacturers

Exhibit 5.37: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue

Exhibit 5.38: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market

Exhibit 5.39: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012

Exhibit 5.40: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2013

Exhibit 5.41: R&D Investment Comparison of Top Indian Pharmaco’s 2010 Vs 2013

Exhibit 5.42: R&D Investment Table of Top Indian Pharmaco’s 2010 Vs 2013

Exhibit 5.43: Investments, Acquisitions and Joint Ventures Between International and Indian Pharmacos

Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest

Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation

Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations

Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest

Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio

Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio

Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio

Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio

Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio

Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio

Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio

Exhibit 6.12: Aurobindo Pharma Alzheimer’s Product Portfolio

Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio

Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio

Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio

Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio

Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio

Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio

Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio

Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio

Exhibit 6.21: Aurobindo Pharma Consolidated Revenue FY2010-FY2013

Exhibit 6.22: Aurobindo Pharma Revenue Breakdown: Formulation and API Sales FY2013

Exhibit 6.23: Aurobindo Pharma Subsidiary Companies

Exhibit 6.24: Aurobindo Pharma Long Term Growth Strategies

Exhibit 6.25: Bharat Serums and Vaccines Significant Milestones

Exhibit 6.26: Bharat Serums and Vaccines Range of Products

Exhibit 6.27: Bharat Serums and Vaccines Plasma Serum Product Portfolio

Exhibit 6.28: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio

Exhibit 6.29: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio

Exhibit 6.30: Bharat Serums and Vaccines Cardiovascular Product Portfolio

Exhibit 6.31: Bharat Serums and Vaccines Anti-microbial Product Portfolio

Exhibit 6.32: Bharat Serums and Vaccines Anti-fungal Product Portfolio

Exhibit 6.33: Bharat Serums and Vaccines Anaesthesia Product Portfolio

Exhibit 6.34: Bharat Serums and Vaccines Hormone Product Portfolio

Exhibit 6.35: Biocon Biopharmaceuticals Business Outline

Exhibit 6.36: Biocon Biopharmaceuticals Five Key Business Areas

Exhibit 6.37: Biocon Biopharmaceuticals Subsidiary Companies

Exhibit 6.38: Biocon Biopharmaceuticals Important Milestones

Exhibit 6.39: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas

Exhibit 6.40: Biocon Biopharmaceuticals Active Biological Product Areas

Exhibit 6.41: Biocon Biopharmaceuticals Diabetes Branded Formulations

Exhibit 6.42: Biocon Biopharmaceuticals Oncology Branded Therapeutics

Exhibit 6.43: Biocon Biopharmaceuticals Nephrology Branded Therapeutics

Exhibit 6.44: Biocon Biopharmaceuticals Cardiology Branded Therapeutics

Exhibit 6.45: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics

Exhibit 6.46: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics

Exhibit 6.47: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics

Exhibit 6.48: Biocon Biopharmaceuticals – Syngene Service Platform

Exhibit 6.49: Biocon Biopharmaceuticals – Clinigene Service Platform

Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2014

Exhibit 6.51: Biocon Biopharmaceuticals Revenue 2008-2014

Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2014

Exhibit 6.53: Biocon Biopharmaceuticals Profits from Operations 2008-2014

Exhibit 6.54: Cipla Important Milestones

Exhibit 6.55: Cipla Main Therapeutics Areas of Interest

Exhibit 6.56: Cipla Export Market Share FY2012-2013

Exhibit 6.57: Cipla Sales and Other Income Exhibits 2003-2013

Exhibit 6.58: Cipla Profit after Tax Figures 2003-2013

Exhibit 6.59: Cipla Significant Product Launches

Exhibit 6.60: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches

Exhibit 6.61: Divis Laboratories Important Milestones

Exhibit 6.62: Divis Laboratories Product Category Portfolio

Exhibit 6.63: Divis Laboratories Product List

Exhibit 6.64: Divis Laboratories Income From Operations 2006-2013

Exhibit 6.65: Divis Laboratories Future Pipeline Portfolio

Exhibit 6.66: Dr Reddy’s Therapeutic Areas of Interest

Exhibit 6.67: Dr Reddy’s Laboratories – Important Milestones

Exhibit 6.68: Dr Reddy’s Labs Top Active Pharmaceutical Ingredients

Exhibit 6.69: Dr Reddy’s Labs Top Brands in India

Exhibit 6.70: Dr Reddy’s Laboratories Annual Revenue Figures 2003-2014

Exhibit 6.71: Dr Reddy’s Laboratories Historical Revenue Figures 2006-2014 (Global)

Exhibit 6.72: Dr Reddy’s Laboratories Geographical Revenue Percentage

Exhibit 6.73: Dr Reddy’s Key Brand Revenue in Russia 2011-2012

Exhibit 6.74: Dr Reddy’s Key Brand Revenue in India 2011-2012

Exhibit 6.75: Dr Reddy’s Therapeutic Agents and Classes undergoing Clinical Trials

Exhibit 6.76: Lupin Significant Milestones

Exhibit 6.77: Lupin Ltd Formulations Product Portfolio

Exhibit 6.78: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio

Exhibit 6.79: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution

Exhibit 6.80: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012

Exhibit 6.81: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution

Exhibit 6.82: Lupin Ltd Geographic Breakdown of Revenue

Exhibit 6.83: Lupin Ltd Net Global Sales 2008-2014

Exhibit 6.84: Lupin Ltd Profit Before Tax 2008-2013

Exhibit 6.85: Lupin Ltd Formulation Sales 2006-2013 Indian Market

Exhibit 6.86: Lupin Ltd Top Product Brands in the Indian Market and Ranking

Exhibit 6.87: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth

Exhibit 6.88: Lupin Pharma Key Products and Rank in the Indian Market

Exhibit 6.89: Lupin Respira Key Products and Rank in the Indian Market

Exhibit 6.90: Lupin Endeavour Key Products and Rank in the Indian Market

Exhibit 6.91: Lupin Maxter Key Products and Rank in the Indian Market

Exhibit 6.92: Lupin Pinnacle CVS Key Products and Rank in the Indian Market

Exhibit 6.93: Lupin Diabetes Care Key Products and Rank in the Indian Market

Exhibit 6.94: Lupin Mindvision Key Products and Rank in the Indian Market

Exhibit 6.95: Lupin Ikonic Key Products and Rank in the Indian Market

Exhibit 6.96: Lupin Pharmaceuticals Formulation Sales US Market 2007-2013

Exhibit 6.97: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market

Exhibit 6.98: Lupin Ltd Percentage Market Share within US Generics Market

Exhibit 6.99: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2014

Exhibit 6.100: Lupin Ltd Division of Sales by Therapeutic Area

Exhibit 6.101: Lupin Ltd Advanced Drug Delivery System Platform Portfolio

Exhibit 6.102: Lupin Ltd Research and Development Areas of Expertise

Exhibit 6.103: Mankind Pharma Company Divisions

Exhibit 6.104: Mankind Pharma Key Milestones

Exhibit 6.105: Mankind Pharma Therapeutic Areas of Interest

Exhibit 6.106: Mankind Pharma Prescription Product Areas

Exhibit 6.107: Mankind Pharma Top Ten Brands

Exhibit 6.108: Mankind Pharma Diabetic Product Brands

Exhibit 6.109: Mankind Pharma Hyperthyroidism Product Brands

Exhibit 6.110: Mankind Pharma Cough Product Brands

Exhibit 6.111: Mankind Pharma Malaria Product Brands

Exhibit 6.112: Mankind Pharma Migraine Product Brands

Exhibit 6.113: Mankind Pharma Anti-viral Product Brands

Exhibit 6.114: Mankind Pharma Steroid Product Brands

Exhibit 6.115: Mankind Pharma Dermatology Product Brands

Exhibit 6.116: Mankind Pharma Ophthalmology Product Brands

Exhibit 6.117: Mankind Pharma Gynaecology Product Brands

Exhibit 6.118: Mankind Pharma Antibiotic Product Brands

Exhibit 6.119: Mankind Pharma Asthmatic Product Brands

Exhibit 6.120: Panacea Biotech Strategic Business Unit Structure

Exhibit 6.121: Panacea Biotech Therapeutic Areas of Interest

Exhibit 6.122: Panacea Biotech Leading Brands in India

Exhibit 6.123: Panacea Biotech Pain Management Therapy Portfolio

Exhibit 6.124: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycaemic Product Range

Exhibit 6.125: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range

Exhibit 6.126: Panacea Biotech Vaccine Portfolio

Exhibit 6.127: Panacea Biotech Diabetes Management Portfolio

Exhibit 6.128: Panacea Biotech Anti-Osteoporotic Portfolio

Exhibit 6.129: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio

Exhibit 6.130: Panacea Biotech Renal Disease Management Portfolio

Exhibit 6.131: Panacea Biotech Gastro Intestinal Product Portfolio

Exhibit 6.132: Panacea Biotech Constipation Product Portfolio

Exhibit 6.133: Panacea Biotech Tuberculosis Product Portfolio

Exhibit 6.134: Panacea Biotech Cough/Cold Product Portfolio

Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care

Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) - Pain Management

Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) – Tuberculosis Treatment

Exhibit 6.138: Panacea Biotech Brand Standing and Market Share (India) – Gastrointestinal Treatment

Exhibit 6.139: Panacea Biotech Brand Standing and Market Share (India) – Anti-Haemorrhoidal

Exhibit 6.140: Panacea Biotech Brand Standing and Market Share (India) – Penicillins

Exhibit 6.141: Panacea Biotech Current Patents for Licencing

Exhibit 6.142: Panacea Biotech Net Turnover 2002-2013

Exhibit 6.143: Panacea Biotech Net Turnover 2002-2013

Exhibit 6.144: Panacea Biotech Geographic Distribution of Sales, 2010-2012

Exhibit 6.145: Panacea Biotech Geographic Distribution of Sales, 2010-2012

Exhibit 6.146: Key Milestones in Piramal Group History

Exhibit 6.147: Piramal Distribution of Sales (Percentage) 2014

Exhibit 6.148: Piramal Distribution of Pharma Solutions Domestic and International Sales (Percentage)

Exhibit 6.149: Piramal Pharma Solutions Sales (Rs Crores) from Domestic and International Assets

Exhibit 6.150: Piramal Oncology Therapeutic Pipeline

Exhibit 6.151: Piramal Inflammation Therapeutic Pipeline

Exhibit 6.152: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline

Exhibit 6.153: Piramal Infectious Disease Therapeutic Pipeline

Exhibit 6.154: Ranbaxy Laboratories – Therapeutic Markets of Interest

Exhibit 6.155: Ranbaxy’s Oral Platform Technologies using a Novel Drug Delivery System

Exhibit 6.156: Ranbaxy Laboratories - Top Ten Therapeutics

Exhibit 6.157: Ranbaxy Key Merger and Acquisition Activity

Exhibit 6.158: List of Ranbaxy Subsidiary Companies

Exhibit 6.159: Ranbaxy – Future Therapeutic Areas

Exhibit 6.160: Ranbaxy Global Sales by Geographical Region FY2014

Exhibit 6.161: Ranbaxy Developed and Emerging Market Share FY2014

Exhibit 6.162: Ranbaxy Sales Figures, USA and Canada, FY2014

Exhibit 6.163: Ranbaxy Sales Figures, Western Europe FY2014

Exhibit 6.164: Ranbaxy Sales Figures, East Europe and CIS FY2014

Exhibit 6.165: Ranbaxy Top Sellers in India

Exhibit 6.166: Ranbaxy Sales Figures, India, 2010-2014

Exhibit 6.167: Ranbaxy Market Share of Top Therapeutics, India

Exhibit 6.168: Ranbaxy Launches by Geographical Region

Exhibit 6.169: Reliance Life Sciences Biopharmaceutical Product Areas

Exhibit 6.170: Reliance Life Sciences Pharmaceutical Product Areas

Exhibit 6.171: Reliance Life Sciences Clinical Research Services

Exhibit 6.172: Reliance Life Sciences Regenerative Medicine Product Areas

Exhibit 6.173: Reliance Life Sciences Molecular Medicine Product Areas

Exhibit 6.174: Reliance Life Science Plasma Protein Product Portfolio

Exhibit 6.175: Reliance Life Science Biosimilar Product Portfolio

Exhibit 6.176: Reliance Life Science Pharmaceutical Product Portfolio

Exhibit 6.177: Reliance Life Science Regenerative Medicine Product Portfolio

Exhibit 6.178: Reliance Life Science R&D Activities

Exhibit 6.179: Serum Institute of India Significant Milestones

Exhibit 6.180: Serum Institute of India Revenue FY2011-2013

Exhibit 6.181: Serum Institute of India Manufactured Products

Exhibit 6.182: Serum Institute of India Marketed Products

Exhibit 6.183: Serum Institute of India Exported Products

Exhibit 6.184: Serum Institute of India Product Pipeline

Exhibit 6.185: Sun Pharmaceuticals Revenue Stream by Formulation, Generics and API’s 2013-2014

Exhibit 6.186: Sun Pharmaceuticals Revenue Stream by Formulation, Generics and API’s 2011-2012

Exhibit 6.187: Sun Pharmaceuticals – Important Milestones

Exhibit 6.188: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions)

Exhibit 6.189: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2013-2014

Exhibit 6.190: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012-2013

Exhibit 6.191: Sun Pharmaceuticals Top Ten Branded Generics in India

Exhibit 6.192: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area

Exhibit 6.193: Zydus Research Centre Speciality Areas of Research

Exhibit 6.194: Zydus Cadila Vaccine R&D Areas of Research

Exhibit 6.195: Zydus Cadila Global ‘Beyond the Billion’ Business Development Strategy

Exhibit 6.196: Zydus Cadila Top Formulation Brands in the Indian Market

Exhibit 6.197: Zydus Cadila New Molecular Entities in Development Pipeline

Exhibit 6.198: Zydus Cadila Biosimilar Therapeutics in Development Pipeline

Exhibit 6.199: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2014

Exhibit 6.200: Zydus Cadila Gross Sales FY2012-FY2014

Exhibit 6.201: Zydus Cadila List of Subsidiary Companies

Exhibit 6.202: Zydus Cadila Key Acquisitions 1995-2012

Exhibit 6.203: Zydus Cadila Research and Development Areas of Interest

Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market

Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020

Exhibit 7.3: Demand Drivers of the Indian Pharmaceutical Industry

Exhibit 7.4: Strengths of the Indian Pharmaceutical Market

Exhibit 7.5: Weaknesses of the Indian Pharmaceutical Market

Exhibit 7.6: Opportunities within the Indian Pharmaceutical Market

Exhibit 7.7: Threats to the Indian Pharmaceutical Market

Exhibit 8.1: Aurobindo Pharma Key Contact Details

Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel

Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details

Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors

Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details

Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors

Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team

Exhibit 8.8: Cipla Executive Directors

Exhibit 8.9: Cipla Non-Executive/Independent Directors

Exhibit 8.10: Cipla Corporate Contact Details

Exhibit 8.11: Divis Laboratories Key Contact Details

Exhibit 8.12: Divis Laboratories Key People

Exhibit 8.13: Dr Reddy’s Laboratories Contact Information

Exhibit 8.14: Dr Reddy’s Laboratories Key People

Exhibit 8.15: Dr Reddy’s Laboratories Board of Directors

Exhibit 8.16: Dr Reddy’s Audit Committee Members

Exhibit 8.17: Dr Reddy’s Nomination, Governance & Compensation Committee Members

Exhibit 8.18: Dr Reddy’s Risk Management Committee Members

Exhibit 8.19: Dr Reddy’s Science, Technology and Operations Committee Members

Exhibit 8.20: Dr Reddy’s Shareholders’ Grievance Committee Members

Exhibit 8.21: Dr Reddy’s Investment Committee Members

Exhibit 8.22: Dr Reddy’s Management Committee Members

Exhibit 8.23: Lupin Board of Directors

Exhibit 8.24: Lupin Key Management Players

Exhibit 8.25: Lupin Ltd General Contact Details

Exhibit 8.26: Panacea Biotech – Whole Time Directors

Exhibit 8.27: Panacea Biotech – Independent Directors

Exhibit 8.28: Panacea Biotech – Investor Contact Details

Exhibit 8.29: Panacea Biotech – General Contact Details

Exhibit 8.30: Reliance Life Sciences – General Contact Details
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Aurobindo Pharma
- Bharat Serums and Vaccines Ltd
- Biocon Biopharmaceuticals
- Cipla
- Divis Laboratories
- Dr Reddy’s Laboratories
- Lupin
- Mankind Pharma
- Panacea Biotech
- Piramal Group
- Ranbaxy Laboratories
- Reliance Life Sciences
- Serum Institute of India
- Sun Pharmaceuticals
- Zydus Cadila
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll